Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL5139128 | 1.00 | ALDH1A1 (0.46) | ALDH1A1LMNAHSD17B10MEN1NPC1 | |
| Acetic Acid SCHEMBL7563017 | 1.00 | ALDH1A1 (0.46) | ALDH1A1LMNAHSD17B10MEN1NPC1 | |
| Acetic Acid SCHEMBL7260355 | 1.00 | ALDH1A1 (0.46) | ALDH1A1LMNAHSD17B10MEN1NPC1 | |
| Acetic Acid SCHEMBL5139315 | 1.00 | ALDH1A1 (0.46) | ALDH1A1LMNAHSD17B10MEN1NPC1 | |
| Acetic Acid SCHEMBL527843 | 1.00 | ALDH1A1 (0.46) | ALDH1A1LMNAHSD17B10MEN1NPC1 | |
| SCHEMBL3316813 | 0.93 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD17B10MEN1NPC1 | |
| SCHEMBL6738634 | 0.83 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD17B10MEN1NPC1 | |
| SCHEMBL27325769 | 0.83 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD17B10MEN1NPC1 | |
| Acetic Acid SCHEMBL3158726 | 0.82 | ALDH1A1 (0.42) | ALDH1A1LMNAHSD17B10MEN1NPC1 | |
| SCHEMBL733874 | 0.82 | MEN1 (0.46) | ALDH1A1LMNAHSD17B10MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024005113-A1 | 3,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND | キッセイ薬品工業株式会社 | 2024-01-04 | — | — | WO | disclosed |
| US-20230405016-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2023-12-21 | — | — | US | disclosed |
| WO-2023114954-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | GENZYME CORPORATION (US) | 2023-06-22 | — | — | WO | disclosed |
| CN-116139138-A | Heterocyclic modulators of lipid synthesis | 3-V生物科学股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20230124641-A1 | CROSS-LINKED NUCLEOSIDE AND NUCLEOTIDE USING SAME | JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF HEALTH SCIENCES (JP) | 2023-04-20 | — | — | US | disclosed |
| US-11622968-B2 | Heterocyclic modulators of lipid synthesis | SAGIMET BIOSCIENCES INC. (US) | 2023-04-11 | — | — | US | disclosed |
| CN-110177551-B | Heterocyclic modulators of lipid synthesis | 3-V生物科学股份有限公司 | 2023-02-17 | — | — | CN | disclosed |
| EP-4108262-A1 | CROSS-LINKED NUCLEOSIDE AND NUCLEOTIDE USING SAME | OSAKA UNIVERSITY (JP) | 2022-12-28 | — | — | EP | disclosed |
| US-20220296605-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2022-09-22 | — | — | US | disclosed |
| US-20220002279-A1 | NOVEL IMIDAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-01-06 | — | — | US | disclosed |
| WO-1998007694-A1 | ACYLAMINOALKENYLENE-AMIDE DERIVATIVES AS NK1 AND NK2 ANTAGONISTS | NOVARTIS AG (CH) | 1998-02-26 | — | — | WO | disclosed |
| WO-1997030029-A1 | PROCESS FOR THE PREPARATION OF 2,2'-BIPYRROLYL-PYRROMETHENE (PRODIGIOSINS) DERIVATIVES | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-08-21 | — | — | WO | disclosed |
| US-5602253-A | STARTING MATERIAL FOR SERINE PROTEASE INHIBITORS | AKTIEBOLAGET ASTRA (SE) | 1997-02-11 | — | — | US | disclosed |
| US-5538997-A | HIV PROTEINASE INHIBITORS | SANDOZ LTD. (CH) | 1996-07-23 | — | — | US | disclosed |
| EP-0701568-A1 | NEW PEPTIDE DERIVATIVES | Astra Aktiebolag (SE) | 1996-03-20 | — | — | EP | disclosed |
| CN-1104209-A | 2,4-diamino-3-hydroxycarboxylic acid derivatives | SANDOZ LTD (CH) | 1995-06-28 | — | — | CN | disclosed |
| WO-1994029336-A1 | NEW PEPTIDE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1994-12-22 | — | — | WO | disclosed |
| EP-0615969-A1 | 2,4-Diamino-3-hydroxycarboxylic acid derivatives | SANDOZ LTD. (CH) | 1994-09-21 | — | — | EP | disclosed |
| US-4732897-A | 4-AZA-17-BETA-SUBSTITUTED-5-ALPHA ANDROSTAN-3-ONES | FARMITALIA CARLO ERBA, S.P.A. (IT) | 1988-03-22 | — | — | US | disclosed |
| EP-0200859-A1 | Steroidal 5-alpha-reductase inhibitors, processes for their preparation and pharmaceutical compositions containing them | FARMITALIA CARLO ERBA S.p.A. (IT) | 1986-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002279-A1 | NOVEL IMIDAZOLE DERIVATIVE | SLC11A2, MLX, LPXN | ALDH1A1 3544/4885LMNA 2762/4885HSD17B10 3152/4885 |
| US-20230405016-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | ALDH1A1 768/4885LMNA 3910/4885HSD17B10 74/4885 |
| US-20220296605-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, SCD | ALDH1A1 724/4885LMNA 3803/4885HSD17B10 57/4885 |
| US-20230124641-A1 | CROSS-LINKED NUCLEOSIDE AND NUCLEOTIDE USING SAME | RNGTT, NUDT1, SLC29A2 | ALDH1A1 585/4885LMNA 1456/4885HSD17B10 1854/4885 |
| US-11622968-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, SCD | ALDH1A1 724/4885LMNA 3803/4885HSD17B10 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.